

IN THE CLAIMS:

The status and content of each claim follows.

1. (currently amended) A jettable solution comprising:
~~a plurality of vesicles each comprising an inner membrane contained within and separate from an outer membrane; [[and]]~~
~~a pharmaceutical payload encapsulated within said inner membrane of each of said vesicles; and~~
an edible liquid vehicle, said plurality of vesicles being stably dispersed in said edible vehicle;
wherein said jettable solution is jettable with an inkjet material dispenser to deliver a specified dosage of said vesicles encapsulating said pharmaceutical payload.
2. (cancelled)
3. (currently amended) The jettable solution of ~~claim 2~~ claim 1, wherein said edible vehicle comprises one of water or an alcohol.
4. (currently amended) The jettable solution of ~~claim 2~~ claim 1, wherein said edible vehicle further comprises a solvent.
5. (currently amended) The jettable solution of claim 1, wherein said plurality of vesicles are formed from a lipid or a mixture of lipids selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidic acids, phosphatidylserines,

phosphatidylglycerols, cardiolipins, poly(ethylene glycol) lipid conjugates polyethylene glycol lipid conjugates, sphingomyelins, cationic lipids, trioctanoin, triolein, dioctanoyl glycerol, cholesterol (~~ovine wool~~), lipid A (~~salmonella minnesota~~), purified lipid A, and dioleoyl-glutaric acid.

6. (withdrawn) The jettable solution of claim 1, wherein said plurality of vesicles are formed from a plurality of di-block copolymers.

7. (currently amended) A jettable solution comprising:
a plurality of vesicles; and
a pharmaceutical payload encapsulated within a central interior of each of said vesicles;

wherein said plurality of vesicles each comprise an outer membrane comprised of two layers of molecules and wherein additional pharmaceutical payload is entrapped between said two layers of molecules of said vesicle outer membrane;

wherein said jettable solution is jettable with an inkjet material dispenser to deliver a specified dosage of said vesicles encapsulating said pharmaceutical payload.

8. (original) The jettable solution of claim 1, wherein said pharmaceutical payload comprises a substantially water-insoluble pharmaceutical.

9. (original) The jettable solution of claim 8, wherein said pharmaceutical payload is selected from the group consisting of Quinidex, Procainamide, Verapamil, Nitroglycerin, Quinidine, Calan, Disopyramide, Sotalol, Mexitil, Pindolol, Isosorbide 5-

mononitrate, Cordarone, Digoxin, Nifedipine, Timolol, Dihydropyridine, Ethmozine, Rythmol, Acebutolol, Penbutolol, Nadolol, Diltiazem, Carteolol, Tambocor, Nicardipine, Captopril, Bepridil, Felodipine, Isradipine, Enalapril, Vasotec, Enalaprilat, Zestril, Esmolol, Univasc, Accupril, Quinapril, Lotensin, Benazepril, Altace, Trandolapril, Amlodipine, Monopril, Fosinopril, Moexipril, and Convert.

10. (original) The jettable solution of claim 1, further comprising a property enhancing agent.

11. (previously presented) The jettable solution of claim 10, wherein said property enhancing agent comprises one of a biocide, a viscosity modifier, a humectant, an antifoaming agent, a surface tension adjusting agent, a rheology adjusting agent, or a pH adjusting agent,.

12. (original) The jettable solution of claim 1, wherein said solution comprises a viscosity of less than 5 centipoise.

13. (original) The jettable solution of claim 1, wherein said solution comprises a surface tension between approximately 25 and 60 dynes per centimeter.

14. (cancelled)

15. (currently amended) The jettable solution of ~~claim 14~~ claim 1, wherein said inkjet material dispenser comprises one of a thermally actuated inkjet dispenser, a

mechanically actuated inkjet dispenser, an electro-statically actuated inkjet dispenser, a magnetically actuated dispenser, a piezo-electrically actuated inkjet dispenser, or a continuous inkjet dispenser.

16. (original) The jettable solution of claim 1, further comprising:

approximately 25 % vehicle;

approximately 2 % vesicle forming component;

approximately 3 to 6 % pharmaceutical payload; and

water.

17. (withdrawn) The jettable solution of claim 1, further comprising:

approximately 3.54 % vitamin E-succinate;

approximately 0.8 % Tris;

approximately 75.64 % water; and

approximately 20 % Diethylene glycol.

18. (withdrawn) The jettable solution of claim 1, further comprising:

approximately 5 % 1,3propanediol;

approximately 3 % Brij30;

approximately 0.15% hexadecyltrimethylammonium bromide (HTAB);

approximately 1 % Cholesterol;

between 5 and 10 % pharmaceutical payload; and

water.

19. (withdrawn) The jettable solution of claim 1, further comprising:
approximately 2.5 % egg yolk or Phosphotidyl choline Soy Lecithin;
approximately 1.0 % Cholic acid Na salt;
approximately 5 % Diethylene glycol;
approximately 5 % pharmaceutical payload; and
water.

20. (withdrawn) The jettable solution of claim 1, further comprising:
approximately 5 % sucrosemono/di stearate;
approximately 5 % 1,3 propane diol;
approximately 5 % pharmaceutical payload; and
water.

21-62. (cancelled)

63. (currently amended) The jettable solution of ~~claim 55~~ claim 1, further comprising a biocide.

64. (currently amended) The jettable solution of ~~claim 55~~ claim 1, further comprising a humectant.

65. (currently amended) The jettable solution of ~~claim 55~~ claim 1, further comprising an antifoaming agent to prevent foaming of said solution.

66. (currently amended) The jettable solution of ~~claim 55~~ claim 1, further comprising a rheology adjusting agent.

67. (currently amended) The jettable solution of ~~claim 55~~ claim 1, further comprising a pH adjusting agent.